Literature DB >> 26118544

Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas.

J Manuel Sarmiento1, Andrew S Venteicher, Chirag G Patil.   

Abstract

BACKGROUND: In most people with low-grade gliomas (LGG), the primary treatment regimen remains a combination of surgery followed by postoperative radiotherapy. However, the optimal timing of radiotherapy is controversial. It is unclear whether to use radiotherapy in the early postoperative period, or whether radiotherapy should be delayed until tumour progression occurs.
OBJECTIVES: To assess the effects of early postoperative radiotherapy versus radiotherapy delayed until tumour progression for low-grade intracranial gliomas in people who had initial biopsy or surgical resection. SEARCH
METHODS: We searched up to September 2014 the following electronic databases: the Cochrane Register of Controlled Trials (CENTRAL, Issue 8, 2014), MEDLINE (1948 to Aug week 3, 2014), and EMBASE (1980 to Aug week 3, 2014) to identify trials for inclusion in this Cochrane review. SELECTION CRITERIA: We included randomised controlled trials (RCTs) that compared early versus delayed radiotherapy following biopsy or surgical resection for the treatment of people with newly diagnosed intracranial LGG (astrocytoma, oligodendroglioma, mixed oligoastrocytoma, astroblastoma, xanthoastrocytoma, or ganglioglioma). Radiotherapy may include conformal external beam radiotherapy (EBRT) with linear accelerator or cobalt-60 sources, intensity-modulated radiotherapy (IMRT), or stereotactic radiosurgery (SRS). DATA COLLECTION AND ANALYSIS: Three review authors independently assessed the trials for inclusion and risk of bias, and extracted study data. We resolved any differences between review authors by discussion. Adverse effects were also extracted from the study report. We performed meta-analyses using a random-effects model with inverse variance weighting. MAIN
RESULTS: We included one large, multi-institutional, prospective RCT, involving 311 participants; the risk of bias in this study was unclear. This study found that early postoperative radiotherapy is associated with an increase in time to progression compared to observation (and delayed radiotherapy upon disease progression) for people with LGG but does not significantly improve overall survival (OS). The median progression-free survival (PFS) was 5.3 years in the early radiotherapy group and 3.4 years in the delayed radiotherapy group (hazard ratio (HR) 0.59, 95% confidence interval (CI) 0.45 to 0.77; P value < 0.0001; 311 participants; 1 trail; low quality evidence). The median OS in the early radiotherapy group was 7.4 years, while the delayed radiotherapy group experienced a median overall survival of 7.2 years (HR 0.97, 95% CI 0.71 to 1.33; P value = 0.872; 311 participants; 1 trail; low quality evidence). The total dose of radiotherapy given was 54 Gy; five fractions of 1.8 Gy per week were given for six weeks. Adverse effects following radiotherapy consisted of skin reactions, otitis media, mild headache, nausea, and vomiting. Rescue therapy was provided to 65% of the participants randomised to delayed radiotherapy. People in both cohorts who were free from tumour progression showed no differences in cognitive deficit, focal deficit, performance status, and headache after one year. However, participants randomised to the early radiotherapy group experienced significantly fewer seizures than participants in the delayed postoperative radiotherapy group at one year (25% versus 41%, P value = 0.0329, respectively). AUTHORS'
CONCLUSIONS: Given the high risk of bias in the included study, the results of this analysis must be interpreted with caution. Early radiation therapy was associated with the following adverse effects: skin reactions, otitis media, mild headache, nausea, and vomiting. People with LGG who undergo early radiotherapy showed an increase in time to progression compared with people who were observed and had radiotherapy at the time of progression. There was no significant difference in overall survival between people who had early versus delayed radiotherapy; however, this finding may be due to the effectiveness of rescue therapy with radiation in the control arm. People who underwent early radiation had better seizure control at one year than people who underwent delayed radiation. There were no cases of radiation-induced malignant transformation of LGG. However, it remains unclear whether there are differences in memory, executive function, cognitive function, or quality of life between the two groups since these measures were not evaluated.

Entities:  

Mesh:

Year:  2015        PMID: 26118544      PMCID: PMC4506130          DOI: 10.1002/14651858.CD009229.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  60 in total

1.  Treatment outcomes and prognostic factors in patients with supratentorial low-grade gliomas.

Authors:  S-A Yeh; J-T Ho; C-C Lui; Y-J Huang; C-Y Hsiung; E-Y Huang
Journal:  Br J Radiol       Date:  2005-03       Impact factor: 3.039

2.  Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up.

Authors:  Linda Douw; Martin Klein; Selene Saa Fagel; Josje van den Heuvel; Martin Jb Taphoorn; Neil K Aaronson; Tjeerd J Postma; W Peter Vandertop; Jacob J Mooij; Rudolf H Boerman; Guus N Beute; Jasper D Sluimer; Ben J Slotman; Jaap C Reijneveld; Jan J Heimans
Journal:  Lancet Neurol       Date:  2009-08-07       Impact factor: 44.182

Review 3.  Radiation oncology in brain tumors: current approaches and clinical trials in progress.

Authors:  Michael D Chan; Stephen B Tatter; Glenn Lesser; Edward G Shaw
Journal:  Neuroimaging Clin N Am       Date:  2010-06-18       Impact factor: 2.264

Review 4.  Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas.

Authors:  J Manuel Sarmiento; Andrew S Venteicher; Chirag G Patil
Journal:  Cochrane Database Syst Rev       Date:  2015-06-29

5.  Phase II trial of temozolomide in patients with progressive low-grade glioma.

Authors:  Jennifer A Quinn; David A Reardon; Allan H Friedman; Jeremy N Rich; John H Sampson; James M Provenzale; Roger E McLendon; Sridharan Gururangan; Darell D Bigner; James E Herndon; Nicholas Avgeropoulos; Jonathan Finlay; Sandra Tourt-Uhlig; Mary Lou Affronti; Brandon Evans; Valerie Stafford-Fox; Sara Zaknoen; Henry S Friedman
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

Review 6.  Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome.

Authors:  G E Keles; K R Lamborn; M S Berger
Journal:  J Neurosurg       Date:  2001-11       Impact factor: 5.115

7.  Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force.

Authors:  R Soffietti; B G Baumert; L Bello; A Von Deimling; H Duffau; M Frénay; W Grisold; R Grant; F Graus; K Hoang-Xuan; M Klein; B Melin; J Rees; T Siegal; A Smits; R Stupp; W Wick
Journal:  Eur J Neurol       Date:  2010-09       Impact factor: 6.089

Review 8.  Glioma extent of resection and its impact on patient outcome.

Authors:  Nader Sanai; Mitchel S Berger
Journal:  Neurosurgery       Date:  2008-04       Impact factor: 4.654

9.  Preoperative prognostic classification system for hemispheric low-grade gliomas in adults.

Authors:  Edward F Chang; Justin S Smith; Susan M Chang; Kathleen R Lamborn; Michael D Prados; Nicholas Butowski; Nicholas M Barbaro; Andrew T Parsa; Mitchel S Berger; Michael M McDermott
Journal:  J Neurosurg       Date:  2008-11       Impact factor: 5.115

10.  Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic.

Authors:  David A Schomas; Nadia N Issa Laack; Ravi D Rao; Fredric B Meyer; Edward G Shaw; Brian Patrick O'Neill; Caterina Giannini; Paul D Brown
Journal:  Neuro Oncol       Date:  2008-11-18       Impact factor: 12.300

View more
  10 in total

1.  [Critical consideration of the European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas].

Authors:  Sophia Scharl; Christoph Straube; Bernhard Meyer; Friederike Schmidt-Graf; Stephanie E Combs
Journal:  Strahlenther Onkol       Date:  2017-11       Impact factor: 3.621

2.  The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma.

Authors:  Ryan S Youland; Cole R Kreofsky; David A Schomas; Paul D Brown; Jan C Buckner; Nadia N Laack
Journal:  J Neurooncol       Date:  2017-08-23       Impact factor: 4.130

Review 3.  Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas.

Authors:  J Manuel Sarmiento; Andrew S Venteicher; Chirag G Patil
Journal:  Cochrane Database Syst Rev       Date:  2015-06-29

Review 4.  Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies.

Authors:  P D Delgado-López; E M Corrales-García; J Martino; E Lastra-Aras; M T Dueñas-Polo
Journal:  Clin Transl Oncol       Date:  2017-03-02       Impact factor: 3.405

5.  Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma.

Authors:  Theresa A Lawrie; David Gillespie; Therese Dowswell; Jonathan Evans; Sara Erridge; Luke Vale; Ashleigh Kernohan; Robin Grant
Journal:  Cochrane Database Syst Rev       Date:  2019-08-05

Review 6.  Clinical practice guidelines for the diagnosis and treatment of adult diffuse glioma-related epilepsy.

Authors:  Shuli Liang; Xing Fan; Ming Zhao; Xia Shan; Wenling Li; Ping Ding; Gan You; Zhen Hong; Xuejun Yang; Guoming Luan; Wenbin Ma; Hui Yang; Yongpin You; Tianming Yang; Liang Li; Weiping Liao; Lei Wang; Xun Wu; Xinguang Yu; Jianguo Zhang; Qing Mao; Yuping Wang; Wenbin Li; Xuefeng Wang; Chuanlu Jiang; Xiaoyan Liu; Songtao Qi; Xingzhou Liu; Yan Qu; Jiwen Xu; Weimin Wang; Zhi Song; Jinsong Wu; Zhixiong Liu; Ling Chen; Yuanxiang Lin; Jian Zhou; Xianzeng Liu; Wei Zhang; Shichuo Li; Tao Jiang
Journal:  Cancer Med       Date:  2019-06-26       Impact factor: 4.452

7.  ETS1-activated SNHG10 exerts oncogenic functions in glioma via targeting miR-532-3p/FBXL19 axis.

Authors:  Lide Jin; Shengquan Huang; Congjin Guan; Shun Chang
Journal:  Cancer Cell Int       Date:  2020-12-09       Impact factor: 5.722

Review 8.  Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas.

Authors:  Shalini Sundramurthi Chelliah; Ervin Ashley Lourdes Paul; Muhamad Noor Alfarizal Kamarudin; Ishwar Parhar
Journal:  Molecules       Date:  2021-02-22       Impact factor: 4.411

9.  Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas.

Authors:  Sanjay Dhawan; Chirag G Patil; Clark Chen; Andrew S Venteicher
Journal:  Cochrane Database Syst Rev       Date:  2020-01-20

10.  Adult Diffuse Low-Grade Gliomas: 35-Year Experience at the Nancy France Neurooncology Unit.

Authors:  Tiphaine Obara; Marie Blonski; Cyril Brzenczek; Sophie Mézières; Yann Gaudeau; Celso Pouget; Guillaume Gauchotte; Antoine Verger; Guillaume Vogin; Jean-Marie Moureaux; Hugues Duffau; Fabien Rech; Luc Taillandier
Journal:  Front Oncol       Date:  2020-10-28       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.